Angiotensin II Antagonists in the Treatment of Hypertension - Effective and Efficient?

Herz

Volumn 28, Issue 8, 2003, Pages 733-737

  Müller Nordhorn, Jacqueline ^a   Willich, Stefan N ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Angiotensin II antagonists; Effectiveness; Efficacy; Efficiency; Hypertension

Indexed keywords

AMLODIPINE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CANDESARTAN; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IRBESARTAN; LOSARTAN; OLMESARTAN; VALSARTAN;

ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; COST BENEFIT ANALYSIS; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; HEALTH CARE COST; HUMAN; HYPERTENSION; KIDNEY FAILURE; QUALITY OF LIFE; REVIEW; SIDE EFFECT; STROKE;

ADRENERGIC BETA-ANTAGONISTS; ANGIOTENSIN II; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; CEREBROVASCULAR ACCIDENT; CLINICAL TRIALS; HUMANS; HYPERTENSION; KIDNEY FAILURE, CHRONIC; TREATMENT OUTCOME;

EID: 0346096501     PISSN: 03409937     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00059-003-2510-z     Document Type: Review

References (21)

1. Canadian Coordinating Office for Health Technology Assessment. Guidelines for the economic evaluation of pharmaceuticals. Ottawa: CCHOTA, 1997.
2. Drummond MF, O'Brien BJ, Stoddart GL, et al. Methods for the economic evaluation of health care programmes. Oxford: Oxford University Press, 1997.
3. McIntyre H, Costa FV, Düsing R, et al. The role of losartan in cost-effective hypertension control. Curr Med Res Opin 2002;18:139-45.
4. Conlin PR, Spence D, Williams B, et al. Angiotensin II antagonists for hypertension: are there differences in efficacy? Am J Hypertens 2000;13:418-26.
5. Oparil S, Williams D, Chrysant SG, et al. Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension. J Clin Hypertens 2001;3:283-91, 318.
6. Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003;289:2560-72.
7. Dahlöf B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2000;359:995-1003.
8. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851-60.
9. Parving HH, Lehnert H, Bröchner-Mortensen J, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001;345:870-8.
10. Brenner BM, Cooper ME, De Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-9.
11. Dickstein K, Kjekshus J, and the OPTIMAAL Steering Committee, for the OPTIMAAL Study Group. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Lancet 2002;360:752-60.
12. Cohn JN, Tognoni G, for the Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001;345:1667-75.
13. Pitt B, Poole-Wilson PA, Segal R, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial - the Losartan Heart Failure Survival Study ELITE II. Lancet 2000;355:1582-7.
14. Lithell H, Hansson L, Skoog I, et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 2003;21:875-86.
15. Psaty BM, Lumley T, Furberg CD, et al. Health outcomes associated with various antihypertensive therapies used as first-line agents. JAMA 2003;289:2534-44.
16. Simons WR. Comparative cost effectiveness of angiotensin II receptor blockers in a US managed care setting. Pharmacoeconomics 2003;21:61-74.
17. Anderson AN, Wessels F, Moodley I, et al. AT1 receptor blockers - cost-effectiveness within the South African context. S Afr Med 2000;90:494-8.
18. Herman WH, Shahinfar S, Carides GW, et al. Losartan reduces the costs associated with diabetic end-stage renal disease. Diabetes Care 2003;26:683-7.
19. Dasbach EJ, Rich MW, Segal R, et al. The cost-effectiveness of losartan versus captopril in patients with symptomatic heart failure. Cardiology 1999;91:189-94.
20. Pitt B, Segal R, Martinez FA, et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 1997;349:747-52.
21. Dickstein K. ELITE II and Val-HeFT are different trials: together what do they tell us? Curr Control Trials Cardiovasc Med 2001;2:240-3.